Development of Immunotherapy for Pancreatic Cancer

Yutaka Kawakami, Takaho Okada, Masanori Akada

    Research output: Contribution to journalArticlepeer-review

    14 Citations (Scopus)

    Abstract

    Human tumor antigens recognized by T cells have been recently identified in various cancers, including pancreatic cancer. With the identified antigens, new immunotherapies can be developed using more efficient immunologic intervention (due to sufficient amounts of antigens in a more immunogenic form), as well as more quantitative and qualitative immunomonitoring. Various immunotherapies for patients with various cancers, including pancreatic cancer, are currently under evaluation in clinical trials. These include adoptive transfer of tumor reactive T cells and LAK cells; nonmyeloablative stem cell transplantation; active immunization with the identified tumor antigens, various tumor-derived products, dendritic cells pulsed with tumor antigens, and gene-modified tumor cells. Although these efforts in the realm of pancreatic cancer are still limited, various groups in Japan continue to be actively involved in this field of research.

    Original languageEnglish
    Pages (from-to)320-325
    Number of pages6
    JournalPancreas
    Volume28
    Issue number3
    DOIs
    Publication statusPublished - 2004 Apr 1

    Keywords

    • Dendritic cells
    • Graft versus tumor effects
    • Immunotherapy
    • T cells
    • Tumor antigens

    ASJC Scopus subject areas

    • Internal Medicine
    • Endocrinology, Diabetes and Metabolism
    • Hepatology
    • Endocrinology

    Fingerprint

    Dive into the research topics of 'Development of Immunotherapy for Pancreatic Cancer'. Together they form a unique fingerprint.

    Cite this